Tesamorelin - Theratechnologies

Drug Profile

Tesamorelin - Theratechnologies

Alternative Names: EGRIFTA; Tesamorelin acetate; TH-9507; ThGRF 1-44

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theratechnologies
  • Developer National Heart, Lung and Blood Institute; National Institute on Aging; Theratechnologies
  • Class Pituitary hormone releasing hormones
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lipodystrophy
  • Phase II Mild cognitive impairment; Non-alcoholic steatohepatitis
  • Discontinued Insomnia; Lipid metabolism disorders; Muscular atrophy

Most Recent Events

  • 04 Jul 2018 Theratechnologies files sNDA for single-vial formulation of tesamorelin for Lipodystrophy in USA
  • 30 May 2018 Theratechnologies and EMD Serono amend the termination agreement for early and final payment of remaining obligations related to tesamorelin
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top